175 results
Page 4 of 9
8-K
EX-99.2
r3zl 282a1zh7g1oelgs
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
z5m 7yyq6i
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
n7fq6b6 qepwaw
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-99.1
nxamthxi
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
tedrp7t9eg
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
vd2he0
2 Mar 21
Regulation FD Disclosure
8:00am
424B5
kjejk9pn 64xnpx6f
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
plk5np
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.1
7kwve m6caji4h
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
oviay34 0pmk9p
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
8h91o3h0g n0b
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
mj7wo3ijlhpbh895y
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
ldkth owp1we
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
EX-99.1
kdwag24 h2to
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.1
sbslcxcq
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm